Perceptive Advisors’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Perceptive Advisors’s Portfolio SGMO Stock Details SGMO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-25,000	Closed	-$355K	–	129
2018 Q2	$355K	Hold	25,000	–	–	0.01%	115
2018 Q1	$475K	Buy	+25,000	New	+$534K	0.01%	123
2017 Q1	–	Sell	-272	Closed	-$1K	–	195
2016 Q4	$1K	Hold	272	–	–	﹤0.01%	179
2016 Q3	$1K	Buy	+272	New	+$1.38K	﹤0.01%	191
2015 Q3	–	Sell	-800,000	Closed	-$8.87M	–	181
2015 Q2	$8.87M	Hold	800,000	–	–	0.53%	44
2015 Q1	$12.5M	Hold	800,000	–	–	0.97%	28
2014 Q4	$12.2M	Hold	800,000	–	–	1.02%	30
2014 Q3	$8.63M	Hold	800,000	–	–	0.87%	31
2014 Q2	$12.2M	Hold	800,000	–	–	1.2%	26
2014 Q1	$14.5M	Buy	+800,000	New	+$15.4M	1.52%	20
2013 Q4	–	Sell	-965,000	Closed	-$10.1M	–	130
2013 Q3	$10.1M	Buy	+965,000	New	+$9.58M	0.82%	32

Other funds holding SGMO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Perceptive Advisors's SGMO Position: Q3 2018 in Review

Perceptive Advisors sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q3 2018, closing a stake of 25,000 shares — an estimated $355K sold.

Perceptive Advisors first reported a position in SGMO in Q3 2013 and held it in 11 quarters. The position peaked at $14.5M in Q1 2014. 217 funds tracked by Wall St. Rank hold SGMO as of Q3 2018.

Perceptive Advisors reported no remaining SANGAMO THERAPEUTICS INC position as of Q3 2018 after selling out during the quarter.
Perceptive Advisors sold 25,000 SANGAMO THERAPEUTICS INC shares in Q3 2018, an estimated $355K.
Perceptive Advisors first reported a position in SANGAMO THERAPEUTICS INC in Q3 2013 and held it in 11 quarters.
Perceptive Advisors's SANGAMO THERAPEUTICS INC position peaked at $14.5M in Q1 2014.
217 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q3 2018.

Based on Perceptive Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.